| Impact of Exigent Research Network’s partnership with the Tempus AI TIME Program on the screening and matching of patients for clinical trials. A Gajra, S Mallahan, S Blau, JA Peguero, M Shoukier, M Kanaan, ... Journal of Clinical Oncology 42 (16_suppl), e13599-e13599, 2024 | | 2024 |
| Phase 1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1 inhibitor, combined with pembrolizumab in patients with anti-PD1 resistant advanced solid tumors: Updated … UN Vaishampayan, RF Sweis, D Kilari, AA Tarhini, JF Gainor, MA Barve, ... Journal of Clinical Oncology 42 (16_suppl), 2507-2507, 2024 | | 2024 |
| Mosunetuzumab and polatuzumab vedotin demonstrates preliminary efficacy in elderly unfit/frail patients with previously untreated diffuse large B-cell lymphoma AJ Olszewski, H Eradat, A Avigdor, NA Horowitz, S Babu, I Levi, ... Blood 142, 855, 2023 | 8 | 2023 |
| 666 Safety, efficacy, and biomarker results of SRK-181, a latent TGFβ1 inhibitor, in anti-PD-1 resistant metastatic ccRCC patients T Yap, UN Vaishampayan, D Kilari, R Sweis, M Barve, J Gainor, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| 1076TiP First-in-human study of ABBV-514 as monotherapy and in combination with budigalimab in patients with advanced solid tumors S Babu, S Kondo, N Ammakkanavar, AI Spira, R Perets, T Doi, J Bar, ... Annals of Oncology 34, S647-S648, 2023 | | 2023 |
| Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer KN Chi, D Rathkopf, MR Smith, E Efstathiou, G Attard, D Olmos, JY Lee, ... Journal of Clinical Oncology 41 (18), 3339-3351, 2023 | 133 | 2023 |
| 1O Safety, pharmacokinetics, efficacy, and biomarker results of SRK-181 (a latent TGFβ1 inhibitor) from a phase I trial (DRAGON trial) TA Yap, J Gainor, M McKean, B Bockorny, M Barve, R Sweis, ... ESMO Open 8 (1), 2023 | | 2023 |
| Abstract GS3-01: GS3-01 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2-metastatic breast cancer: updated results by … A Bardia, FC Bidard, P Neven, G Streich, AJ Montero, F Forget, ... Cancer research 83 (5_Supplement), GS3-01-GS3-01, 2023 | 9 | 2023 |
| RELATIVITY-123: A phase 3, randomized, open-label study of nivolumab (NIVO)+ relatlimab (RELA) fixed-dose combination (FDC) versus regorafenib or trifluridine+ tipiracil (TAS … K Feeney, WL Joubert, RE Bordoni, S Babu, S Marimuthu, B Hipkin, ... Journal of Clinical Oncology 41 (4_suppl), TPS278-TPS278, 2023 | 2 | 2023 |
| Erratum: Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2 … FC Bidard, VG Kaklamani, P Neven, G Streich, AJ Montero, F Forget, ... Journal of clinical oncology: official journal of the American Society of …, 2023 | 1 | 2023 |
| Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine DA Pollyea, KW Pratz, AH Wei, V Pullarkat, BA Jonas, C Recher, S Babu, ... Clinical Cancer Research 28 (24), 5272-5279, 2022 | 71 | 2022 |
| Mosunetuzumab monotherapy continues to demonstrate promising efficacy and durable complete responses in elderly/unfit patients with previously untreated diffuse large B-cell … AJ Olszewski, A Avigdor, S Babu, I Levi, H Eradat, U Abadi, H Holmes, ... Blood 140 (Supplement 1), 1778-1780, 2022 | 21 | 2022 |
| ELN risk stratification is not predictive of outcomes for treatment-naïve patients with acute myeloid leukemia treated with venetoclax and azacitidine H Döhner, KW Pratz, CD DiNardo, BA Jonas, VA Pullarkat, MJ Thirman, ... Blood 140 (Supplement 1), 1441-1444, 2022 | 48 | 2022 |
| Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor–positive, human epidermal growth factor receptor 2–negative … FC Bidard, VG Kaklamani, P Neven, G Streich, AJ Montero, F Forget, ... Journal of Clinical Oncology 40 (28), 3246-3256, 2022 | 313 | 2022 |
| OA12. 03 Phase 2 study analysis of talazoparib (TALA) plus temozolomide (TMZ) for extensive-stage small cell lung cancer (ES-SCLC) J Goldman, A Cummings, M Mendenhall, MA Velez, S Babu, T Johnson, ... Journal of Thoracic Oncology 17 (9), S32, 2022 | 4 | 2022 |
| Primary analysis from the phase 2 study of continuous talazoparib (TALA) plus intermittent low-dose temozolomide (TMZ) in patients with relapsed or refractory extensive-stage … JW Goldman, AL Cummings, MA Mendenhall, MA Velez, S Babu, ... Journal of Clinical Oncology 40 (16_suppl), 8517-8517, 2022 | 10 | 2022 |
| Phase Ib/II study of enzalutamide with samotolisib (LY3023414) or placebo in patients with metastatic castration-resistant prostate cancer CJ Sweeney, IJ Percent, S Babu, JL Cultrera, BA Mehlhaff, OB Goodman, ... Clinical Cancer Research 28 (11), 2237-2247, 2022 | 19 | 2022 |
| Abstract GS2-02: Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/metastatic breast … A Bardia, P Neven, G Streich, AJ Montero, F Forget, MA Mouret-Reynier, ... Cancer Research 82 (4_Supplement), GS2-02-GS2-02, 2022 | 43 | 2022 |
| Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax combined with hypomethylating agents DA Pollyea, KW Pratz, AH Wei, VA Pullarkat, BA Jonas, C Recher, S Babu, ... Blood 138, 224, 2021 | 25 | 2021 |
| Poster: ABCL-366: Mosunetuzumab (Mosun) Monotherapy for Elderly/Unfit Patients with First-Line Diffuse Large B-Cell Lymphoma (DLBCL) Continues to Show Promising Safety and … A Olszewski, A Avigdor, S Babu, I Levi, H Eradat, U Abadi, H Holmes, ... Clinical Lymphoma Myeloma and Leukemia 21, S239, 2021 | | 2021 |
